Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Venous Thromboembolism 5Venous Thrombosis 4Pulmonary Embolism 4Neoplasms 4Thrombosis 2Neoplasm Metastasis 2Intracranial Thrombosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Mesenteric Ischemia 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 130Methotrexate 93fludarabine phosphate 74Cytarabine 71Vincristine 66Whole-Body Irradiation 65Mycophenolic Acid 58Dexamethasone 55Tacrolimus 49Peripheral Blood Stem Cell Transplantation 48fludarabine 47Busulfan 46pegaspargase 43Filgrastim 41Etoposide 41Doxorubicin 41Calcium Dobesilate 40Granulocyte Colony-Stimulating Factor 39Rituximab 36Cyclosporine 36Mercaptopurine 35Melphalan 33Prednisone 31merphos 28Clofarabine 26Asparaginase 26Antilymphocyte Serum 25Leucovorin 23Daunorubicin 23Thiotepa 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor Cell Lymphoblastic Leukemia-Lymphoma × apixaban × Clear all
NCT02369653 2022-03-08

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Bristol-Myers Squibb

Phase 3 Completed
512 enrolled 26 charts
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡